<DOC>
	<DOCNO>NCT00263640</DOCNO>
	<brief_summary>The trial perform assess efficacy safety Allergopharma house dust mite allergoid bronchial asthma .</brief_summary>
	<brief_title>Safety Efficacy House Dust Mite Allergoid Treatment Bronchial Asthma</brief_title>
	<detailed_description>The rationale present study demonstrate clinical efficacy tolerability compare placebo phase III clinical study pivotal character representative number patient suffer fully reversible asthma +/- allergic rhinitis . This condition present paediatric adult patient short history GINA II III asthma , investigate study .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Respiratory Hypersensitivity</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Bronchial asthma Requirements inhale corticosteroid Positive skin prick test house dust mite Positive radioallergosorbent test ( RAST ) house dust mite Positive provocation test result house dust mite Serious chronic diseases Other perennial allergy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>House dust mite</keyword>
	<keyword>Bronchial Asthma</keyword>
	<keyword>Allergy</keyword>
	<keyword>House Dust Mite Allergy</keyword>
</DOC>